TIE-ADC™ Program
Triple Negative Breast Cancer (TNBC) and Non-Small Cell Lung Cancer (NSCLC)
Pre-clinicalActive
Key Facts
Indication
Triple Negative Breast Cancer (TNBC) and Non-Small Cell Lung Cancer (NSCLC)
Phase
Pre-clinical
Status
Active
Company
About TRIO Pharmaceuticals
TRIO Pharmaceuticals is a preclinical-stage biotech pioneering a novel class of dual-targeting antibodies designed to kill cancer cells more precisely while simultaneously overcoming the immunosuppressive tumor microenvironment. Its two core platforms, TIE-ADC™ and TRAILBody™, address key limitations of current therapies—toxicity and immune evasion—across a pipeline focused on AML/MDS, ovarian/endometrial cancer, TNBC, and NSCLC. Founded by experienced drug developers with prior successful exits, the company is positioned to advance its candidates toward clinical development, targeting areas of high unmet medical need.
View full company profile